Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer

Adding zipalertinib to platinum-pemetrexed chemotherapy importantly improved progression-free endurance successful patients receiving first-line attraction for precocious non-small compartment lung crab (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).